
TY  - JOUR
TI  - Oral Abstracts
JO  - American Journal of Transplantation
VL  - 11
IS  - s2
SN  - 1600-6135
UR  - https://doi.org/10.1111/j.1600-6143.2011.03533.x
DO  - doi:10.1111/j.1600-6143.2011.03533.x
SP  - 28
EP  - 211
PY  - 2011
ER  - 

TY  - JOUR
TI  - ANZSBT oral abstracts presented at the HSANZ/ANZSBT/ASTH with APSTH Annual Scientific Meeting, Melbourne, 28–31 October 2012
JO  - Transfusion Medicine
JA  - Transfusion Med
VL  - 23
IS  - 4
SN  - 0958-7578
UR  - https://doi.org/10.1111/tme.12055
DO  - doi:10.1111/tme.12055
SP  - 287
EP  - 298
PY  - 2013
ER  - 

AU  - Bourke, Billy
AU  - Hussey, Séamus
C7  - pp. 1249-1263
TI  - Chronic Infections of the Small Intestine
SN  - 9781118512067
UR  - https://doi.org/10.1002/9781118512074.ch63
DO  - doi:10.1002/9781118512074.ch63
SP  - 1249-1263
KW  - mycotic infections
KW  - small intestine
KW  - small-bowel biopsy
KW  - tropical sprue
KW  - tuberculosis
KW  - Whipple's disease
PY  - 2013
AB  - Summary The advent of molecular genetic techniques and successful cell culture of the organism towards the end of the 20th century substantially accelerated the understanding of the causative organism, Tropheryma whipplei, and by extension, the underlying clinical condition. Whipple's disease usually is diagnosed at an advanced stage and presents with a variety of clinical manifestations. In classic Whipple's disease small-bowel biopsy usually establishes the diagnosis. The effectiveness of antimicrobials, especially poorly absorbed antibiotics, as the mainstay for treating tropical sprue establishes the central role of enteric bacteria/bacterial overgrowth in the condition. Mycotic infections usually arise from disseminated pulmonary infections and occur usually, but not exclusively, in immunocompromised patients. The differential diagnosis for all mycotic infections of the small intestine is similar and includes other mycotic infections, Crohn's disease, tuberculosis (TB) enteritis, disseminated mycobacterium avium complex (MAC), bacterial typhlitis, intestinal ischemia and carcinoma.
ER  - 

TY  - JOUR
TI  - Posters Group 1 - Immunology
JO  - Allergy
VL  - 56
IS  - S68
SN  - 9781118512067
UR  - https://doi.org/10.1111/j.1398-9995.2001.tb05137.x
DO  - doi:10.1111/j.1398-9995.2001.tb05137.x
SP  - 108
EP  - 145
PY  - 2001
ER  - 

TY  - JOUR
TI  - Abstracts
JO  - Muscle & Nerve
JA  - Muscle Nerve
VL  - 46
IS  - 4
SN  - 9781118512067
UR  - https://doi.org/10.1002/mus.23652
DO  - doi:10.1002/mus.23652
SP  - 621
EP  - 679
PY  - 2012
ER  - 

TY  - JOUR
TI  - Abstracts
JO  - Journal of Thrombosis and Haemostasis
VL  - 3
IS  - s1
SN  - 9781118512067
UR  - https://doi.org/10.1111/j.1538-7836.2005.0300b.x
DO  - doi:10.1111/j.1538-7836.2005.0300b.x
SP  - OR001
EP  - OR396
PY  - 2005
ER  - 

TY  - JOUR
AU  - Daigo, Kenji
AU  - Inforzato, Antonio
AU  - Barajon, Isabella
AU  - Garlanda, Cecilia
AU  - Bottazzi, Barbara
AU  - Meri, Seppo
AU  - Mantovani, Alberto
TI  - Pentraxins in the activation and regulation of innate immunity
JO  - Immunological Reviews
JA  - Immunol Rev
VL  - 274
IS  - 1
SN  - 9781118512067
UR  - https://doi.org/10.1111/imr.12476
DO  - doi:10.1111/imr.12476
SP  - 202
EP  - 217
KW  - cancer-related inflammation
KW  - complement activation
KW  - inflammation
KW  - opsonization
KW  - pentraxins
KW  - PTX3
PY  - 2016
AB  - Summary Humoral fluid phase pattern recognition molecules (PRMs) are a key component of the activation and regulation of innate immunity. Humoral PRMs are diverse. We focused on the long pentraxin PTX3 as a paradigmatic example of fluid phase PRMs. PTX3 acts as a functional ancestor of antibodies and plays a non-redundant role in resistance against selected microbes in mouse and man and in the regulation of inflammation. This molecule interacts with complement components, thus modulating complement activation. In particular, PTX3 regulates complement-driven macrophage-mediated tumor progression, acting as an extrinsic oncosuppressor in preclinical models and selected human tumors. Evidence collected over the years suggests that PTX3 is a biomarker and potential therapeutic agent in humans, and pave the way to translation of this molecule into the clinic.
ER  - 

TY  - JOUR
TI  - Poster Session
JO  - The Journal of Dermatology
VL  - 39
IS  - s1
SN  - 9781118512067
UR  - https://doi.org/10.1111/j.1346-8138.2012.01624.x
DO  - doi:10.1111/j.1346-8138.2012.01624.x
SP  - 53
EP  - 280
PY  - 2012
ER  - 

TY  - JOUR
TI  - Oral Presentations
JO  - Journal of Tissue Engineering and Regenerative Medicine
JA  - J Tissue Eng Regen Med
VL  - 8
IS  - s1
SN  - 9781118512067
UR  - https://doi.org/10.1002/term.1931
DO  - doi:10.1002/term.1931
SP  - 39
EP  - 206
PY  - 2014
ER  - 

TY  - JOUR
AU  - Han, Mingzhi
AU  - Wang, Shuai
AU  - Yang, Ning
AU  - Wang, Xu
AU  - Zhao, Wenbo
AU  - Saed, Halala Sdik
AU  - Daubon, Thomas
AU  - Huang, Bin
AU  - Chen, Anjing
AU  - Li, Gang
AU  - Miletic, Hrvoje
AU  - Thorsen, Frits
AU  - Bjerkvig, Rolf
AU  - Li, Xingang
AU  - Wang, Jian
C7  - e10924
TI  - Therapeutic implications of altered cholesterol homeostasis mediated by loss of CYP46A1 in human glioblastoma
JO  - EMBO Molecular Medicine
JA  - EMBO Mol Med
VL  - 12
IS  - 1
SN  - 9781118512067
UR  - https://doi.org/10.15252/emmm.201910924
DO  - doi:10.15252/emmm.201910924
SP  - e10924
KW  - 24OHC
KW  - cholesterol homeostasis
KW  - CYP46A1
KW  - efavirenz
KW  - glioblastoma
PY  - 2020
AB  - Abstract Dysregulated cholesterol metabolism is a hallmark of many cancers, including glioblastoma (GBM), but its role in disease progression is not well understood. Here, we identified cholesterol 24-hydroxylase (CYP46A1), a brain-specific enzyme responsible for the elimination of cholesterol through the conversion of cholesterol into 24(S)-hydroxycholesterol (24OHC), as one of the most dramatically dysregulated cholesterol metabolism genes in GBM. CYP46A1 was significantly decreased in GBM samples compared with normal brain tissue. A reduction in CYP46A1 expression was associated with increasing tumour grade and poor prognosis in human gliomas. Ectopic expression of CYP46A1 suppressed cell proliferation and in vivo tumour growth by increasing 24OHC levels. RNA-seq revealed that treatment of GBM cells with 24OHC suppressed tumour growth through regulation of LXR and SREBP signalling. Efavirenz, an activator of CYP46A1 that is known to penetrate the blood?brain barrier, inhibited GBM growth in vivo. Our findings demonstrate that CYP46A1 is a critical regulator of cellular cholesterol in GBM and that the CYP46A1/24OHC axis is a potential therapeutic target.
ER  - 

TY  - JOUR
C7  - e25093
TI  - Speaker Abstracts
JO  - Journal of the International AIDS Society
JA  - J Intern AIDS Soc
VL  - 21
IS  - S3
SN  - 9781118512067
UR  - https://doi.org/10.1002/jia2.25093
DO  - doi:10.1002/jia2.25093
SP  - e25093
PY  - 2018
ER  - 

TY  - JOUR
TI  - Poster Session A
JO  - Tropical Medicine & International Health
VL  - 14
IS  - s2
SN  - 9781118512067
UR  - https://doi.org/10.1111/j.1365-3156.2009.02354_1.x
DO  - doi:10.1111/j.1365-3156.2009.02354_1.x
SP  - 98
EP  - 159
PY  - 2009
ER  - 

C7  - pp. 584-658
TI  - Cardiac Regenerative Engineering
SN  - 9780471709077
UR  - https://doi.org/10.1002/9780470116869.ch14
DO  - doi:10.1002/9780470116869.ch14
SP  - 584-658
KW  - cardiac regenerative engineering and cardiac disorders
KW  - Vascular endothelial growth factor (VEGF) A
KW  - antioxidant molecules and therapeutic agents
PY  - 2009
AB  - Summary This chapter contains sections titled: Anatomy and Physiology of the Heart Cardiac Disorders
ER  - 

TY  - JOUR
AU  - Marcovina, S. M.
AU  - Crea, F.
AU  - Davignon, J.
AU  - Kaski, J. C.
AU  - Koenig, W.
AU  - Landmesser, U.
AU  - Pieri, P. L.
AU  - Schulz-Menger, J.
AU  - Shaw, L. J.
AU  - Sobesky, J.
TI  - Biochemical and bioimaging markers for risk assessment and diagnosis in major cardiovascular diseases: a road to integration of complementary diagnostic tools
JO  - Journal of Internal Medicine
VL  - 261
IS  - 3
SN  - 9780471709077
UR  - https://doi.org/10.1111/j.1365-2796.2006.01734.x
DO  - doi:10.1111/j.1365-2796.2006.01734.x
SP  - 214
EP  - 234
KW  - acute coronary syndrome
KW  - biochemical markers
KW  - bioimaging cardiovascular disease
KW  - congestive heart failure
KW  - stroke
PY  - 2007
AB  - Abstract. This report from the first International Course on Integrated Biomarkers, Biochemical and Bioimaging Endpoints in Cardiovascular Diagnosis, Prevention, Therapy and Drug Development provides the basis for optimizing diagnostic, prognostic and therapeutic information in four areas of cardiovascular medicine: primary prevention of cardiovascular diseases, acute coronary syndromes, heart failure and stroke. Risk stratification and treatment strategies can be refined and enhanced through integration of bioimaging and biochemical markers to characterize sub-clinical and clinical atherosclerosis. For the integrative approach to be useful, each of the biomarkers must be validated and cost-effective. Clinical decision is the primary level of integration and is based on clinical evaluation and the use of a combination of bioimaging and biochemical markers. The decision to initiate preventive or therapeutic intervention must take into account the factors affecting the levels of expression of the biomarker and the potential input the biomarker has on metabolic processes or modulation of other biomarkers. The optimal approach to intervention must take into consideration the risk?benefit and cost?effectiveness ratios.
ER  - 

TY  - JOUR
TI  - Abstracts From 2017 NANS 20th Annual Meeting, Las Vegas, NV, USA January 19-22, 2017
JO  - Neuromodulation: Technology at the Neural Interface
JA  - Neuromodulation: Technology at the Neural Interface
VL  - 20
IS  - 7
SN  - 9780471709077
UR  - https://doi.org/10.1111/ner.12639
DO  - doi:10.1111/ner.12639
SP  - e122
EP  - e335
PY  - 2017
ER  - 

TY  - JOUR
TI  - 23Rd Clinical Congress Abstracts Papers
JO  - Journal of Parenteral and Enteral Nutrition
JA  - Journal of Parenteral and Enteral Nutrition
VL  - 23
IS  - 1
SN  - 9780471709077
UR  - https://doi.org/10.1177/014860719902300111
DO  - doi:10.1177/014860719902300111
SP  - S1
EP  - S24
PY  - 1999
ER  - 

TY  - JOUR
TI  - Research Abstract Program of the 2011 ACVIM Forum Denver, Colorado, June 15–18, 2011
JO  - Journal of Veterinary Internal Medicine
VL  - 25
IS  - 3
SN  - 9780471709077
UR  - https://doi.org/10.1111/j.1939-1676.2011.0726.x
DO  - doi:10.1111/j.1939-1676.2011.0726.x
SP  - 632
EP  - 767
PY  - 2011
ER  - 

TY  - JOUR
TI  - POSTER DISCUSSION SESSIONS
JO  - Allergy
VL  - 63
IS  - s88
SN  - 9780471709077
UR  - https://doi.org/10.1111/j.1398-9995.2008.01759.x
DO  - doi:10.1111/j.1398-9995.2008.01759.x
SP  - 78
EP  - 157
PY  - 2008
ER  - 

TY  - JOUR
TI  - P941 - P1197
JO  - Clinical Microbiology and Infection
VL  - 12
IS  - s4
SN  - 9780471709077
UR  - https://doi.org/10.1111/j.1470-9465.2006.12_4_1429.x
DO  - doi:10.1111/j.1470-9465.2006.12_4_1429.x
PY  - 2006
ER  - 

TY  - JOUR
TI  - American Society of Pediatric Hematology/Oncology 18th Annual Meeting: Abstracts
JO  - Pediatric Blood & Cancer
JA  - Pediatr. Blood Cancer
VL  - 44
IS  - 6
SN  - 9780471709077
UR  - https://doi.org/10.1002/pbc.20423
DO  - doi:10.1002/pbc.20423
SP  - 529
EP  - 577
PY  - 2005
ER  - 
